Literature DB >> 20578969

Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay.

Diana Koletzki1, Stéphanie Dumont, Hans Vermeiren, Bart Fevery, Pieter De Smet, Lieven J Stuyver.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) genotyping and accurate subtype determination is becoming increasingly important to better understand viral evolution, the development of resistance to STAT-C, and possibly even for the treatment and management of chronic HCV-infected patients.
METHODS: A subtyping assay based on a 329-bp sequence of the NS5B region, together with an automated subtype interpretation tool was developed. Clinical samples of the six major genotypes were used to assess assay performance characteristics.
RESULTS: The NS5B BLAST-based subtyping assay showed clinical sensitivity for amplification of 89% (n=603 random samples). Assessment of analytical sensitivity of amplification for genotypes 1, 2, 3 and 4 revealed a suitable performance for high viral load samples and decreased only with low viral loads. The results were 100% and 99% accurate at the genotype and subtype level, respectively. A concordance of 97% on genotype level and 62% on subtype level was observed by comparison with subtype results from 5' non-coding-based assays with a panel of 276 isolates.
CONCLUSIONS: The HCV NS5B subtyping assay has been validated for research use. Based on its performance, it is the method of choice in cases where subtype rather than genotype information is needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578969     DOI: 10.1515/CCLM.2010.236

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  9 in total

1.  Nine additional complete genome sequences of HCV genotype 6 from Vietnam including new subtypes 6xb and 6xc.

Authors:  Chunhua Li; Van H Pham; Kenji Abe; Ling Lu
Journal:  Virology       Date:  2014-08-30       Impact factor: 3.616

2.  The genetic diversity and evolutionary history of hepatitis C virus in Vietnam.

Authors:  Chunhua Li; Manqiong Yuan; Ling Lu; Teng Lu; Wenjie Xia; Van H Pham; An X D Vo; Mindie H Nguyen; Kenji Abe
Journal:  Virology       Date:  2014-09-03       Impact factor: 3.616

3.  Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.

Authors:  Preethi Krishnan; Gretja Schnell; Rakesh Tripathi; Jill Beyer; Thomas Reisch; Tatyana Dekhtyar; Michelle Irvin; Wangang Xie; Bo Fu; Margaret Burroughs; Rebecca Redman; Hiromitsu Kumada; Kazuaki Chayama; Christine Collins; Tami Pilot-Matias
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.

Authors:  Gretja Schnell; Rakesh Tripathi; Preethi Krishnan; Jill Beyer; Thomas Reisch; Michelle Irvin; Tatyana Dekhtyar; Carolyn Setze; Lino Rodrigues; Katia Alves; Margaret Burroughs; Rebecca Redman; Kazuaki Chayama; Hiromitsu Kumada; Christine Collins; Tami Pilot-Matias
Journal:  J Med Virol       Date:  2017-09-22       Impact factor: 2.327

5.  Important factors in reliable determination of hepatitis C virus genotype by use of the 5' untranslated region.

Authors:  Koji Hara; Maria M Rivera; Christopher Koh; Sasan Sakiani; Jay H Hoofnagle; Theo Heller
Journal:  J Clin Microbiol       Date:  2013-03-06       Impact factor: 5.948

6.  Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients.

Authors:  Fatma Houissa Kchouk; Yousr Gorgi; Lamjed Bouslama; Imen Sfar; Rym Ayari; Hacene Khiri; Phillipe Halfon; Houda Aouadi; Saloua Jendoubi Ayed; Khaled Ayed; Taieb Ben Abdallah
Journal:  Viral Immunol       Date:  2013-02-01       Impact factor: 2.257

7.  Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.

Authors:  Gretja Schnell; Rakesh Tripathi; Jill Beyer; Thomas Reisch; Preethi Krishnan; Liangjun Lu; Tatyana Dekhtyar; Coleen Hall; Regis A Vilchez; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

8.  Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.

Authors:  Kazuaki Chayama; Kazuo Notsumata; Masayuki Kurosaki; Ken Sato; Lino Rodrigues; Carolyn Setze; Prajakta Badri; Tami Pilot-Matias; Regis A Vilchez; Hiromitsu Kumada
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

9.  Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o.

Authors:  Bo Wang; Luise Krüger; Patrycja Machnowska; Amare Eshetu; Barbara Gunsenheimer-Bartmeyer; Viviane Bremer; Andrea Hauser; Norbert Bannert; C-Thomas Bock
Journal:  Virol J       Date:  2019-03-04       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.